Dividends Inside 
Novartis AG Sponsored ADR
NVS
$159.90 (+ $5.76 + 3.74%)
Last updated: 2026-07-04 03:09 UTC
Novartis AG Sponsored ADR trades under ticker NVS on NYSE as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US66987V1098, CUSIP 66987V109.
About the Company
Novartis AG Sponsored ADR represents ownership in Novartis AG, a global healthcare company focused on researching, developing, manufacturing, and marketing innovative medicines. Through this ADR structure, U.S. investors can gain exposure to Novartis AG shares in U.S. dollars, with each depositary receipt backed by an underlying Novartis share held by a depositary bank. Novartis today concentrates on prescription pharmaceuticals across key therapeutic areas such as oncology, cardiovascular, immunology, neuroscience, and ophthalmology, offering treatments for a wide range of chronic and acute conditions. The company’s portfolio includes both established medicines and newer targeted and specialty therapies, supported by significant investment in clinical research and development. Novartis AG Sponsored ADR plays a notable role in the global healthcare sector by providing access to a diversified range of branded drugs that serve hospitals, clinics, and pharmacies worldwide, while giving international investors a convenient mechanism to participate in the performance of a major Swiss-based pharmaceutical company.
Price History
Latest News for NVS
Tesla, SMCI, Others See Sharp Analyst Revisions
Sentiment shifts as risks and opportunities emerge
There Are Three Things Driving Amplify’s 5.1%. Yield Higher | IDVO
Most income ETFs draw from a single well: either dividends or options premium. The Amplify CWP International Enhanced Dividend Income ETF (NYSEARCA:IDVO) draws from three simultaneously, and the way it selects holdings is what separates it from passive income funds. The fund targets American Depositary Receipts, the dollar-denominated securities that let U.S. investors own shares ... There Are Three Things Driving Amplify’s 5.1%. Yield Higher | IDVO
Health Care Roundup: Market Talk
1127 ET – Novartis’s share-price strength this year raises the bar for upcoming data on late-stage clinical studies that will be pivotal for the Swiss drugmaker’s outlook, Bank of America analysts say in a research note. Pipeline failure could hit consensus estimates, but success would help shift investors’ focus away from patent expirations, according to Bank of America. Among Novartis’s upcoming phase 3 trials, Bank of America is most focused on remibrutinib in relapse-remitting multiple sclerosis and pelacarsen in secondary prevention of cardiovascular events, the analysts say.
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
New Rhapsido® REMIX-1 & -2 pooled analysis on symptom control as early as week 1 in chronic spontaneous urticaria (CSU) to be presentedLong-term Cosentyx® data build on extensive body of evidence supporting continuous use in hidradenitis suppurativa (HS) and psoriasisAdditional Cosentyx data in HS include indirect comparison of efficacy and safety vs bimekizumab Basel, March 23, 2026 – Novartis will present data from more than 20 abstracts from its growing immunology portfolio at this year’s Ame
Voyager Therapeutics Conference: CEO Calls 2026 “Year of Tau,” Eyes BBB Capsid Clinic Debut
Voyager Therapeutics (NASDAQ:VYGR) CEO Al Sandrock outlined several 2026 priorities in a discussion focused on the company’s tau-directed pipeline and its newer blood-brain barrier (BBB)-penetrant capsid platform. Sandrock described 2026 as “the year of tau,” while also pointing to upcoming clinical
Stocks to Watch Recap: Super Micro Computer, FedEx, Unilever
↗️ FedEx (FDX): The shipping company raised its outlook as revenue increased in the fiscal third quarter. Shares rose 0.8%. ↘️ Super Micro Computer (SMCI): The technology company placed two employees on leave and fired a contractor after learning of their alleged involvement in a scheme to divert computer servers assembled in the U.